Sarepta Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 2, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 2, 2026

SRPT$17.24-3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$801,282	$1,103,010
Short-term investments	138,368	251,782
Accounts receivable, net	398,233	601,988
Inventory	914,744	749,960
Manufacturing-related deposits and prepaids	113,455	276,262
Other current assets	171,856	90,461
Total current assets	2,537,938	3,073,463
Property and equipment, net	345,125	340,336
Right of use assets	125,495	148,310
Non-current inventory	184,543	187,986
Non-current investments	1,048	133,163
Other non-current assets	155,554	79,915
Total assets	$3,349,703	$3,963,173
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$280,841	$214,442
Accrued expenses	359,659	373,513
Deferred revenue, current portion	443,397	130,256
Other current liabilities	11,393	13,473
Total current liabilities	1,095,290	731,684
Long-term debt	828,974	1,137,124
Lease liabilities, net of current portion	199,378	192,473
Deferred revenue, net of current portion	83,910	325,000
Contingent consideration	—	47,400
Other non-current liabilities	1,529	1,750
Total liabilities	2,209,081	2,435,431
Commitments and contingencies (Note 23)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding	—	—
Common stock, $0.0001 par value, 198,000,000 shares authorized; 105,615,096 and 104,964,220 issued and outstanding, respectively, at December 31, 2025 and 96,900,496 issued and outstanding at December 31, 2024	11	10
Treasury stock, at cost, 650,876 and 0 shares at December 31, 2025 and December 31, 2024, respectively	(25,263)	—
Additional paid-in capital	6,042,586	5,738,924
Accumulated other comprehensive income (loss), net of tax	272	(218)
Accumulated deficit	(4,876,984)	(4,210,974)
Total stockholders’ equity	1,140,622	1,527,742
Total liabilities and stockholders’ equity	$3,349,703	$3,963,173

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.